

Catharine M L West

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2796669/publications.pdf>

Version: 2024-02-01

257
papers

13,850
citations

15466

65
h-index

30010

103
g-index

272
all docs

272
docs citations

272
times ranked

16842
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.3	10
2	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. <i>Advances in Radiation Oncology</i> , 2022, 7, 100890.	0.6	6
3	Development and validation of a hypoxia-associated signature for lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 1290.	1.6	6
4	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. <i>British Journal of Cancer</i> , 2022, 126, 1082-1090.	2.9	12
5	Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer. <i>British Journal of Cancer</i> , 2022, , .	2.9	0
6	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
7	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	0.9	5
8	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2203-2212.	0.8	10
9	Effect of Race and Ethnicity on Risk of Radiotherapy Toxicity and Implications for Radiogenomics. <i>Clinical Oncology</i> , 2022, 34, 653-669.	0.6	6
10	Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature. <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	2
11	Identifying the Radioresponsive Genome for Genomics-Guided Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 223-224.	3.0	3
12	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 201-208.	0.8	2
13	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
14	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
15	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
16	Developing Tumor Radiosensitivity Signatures Using LncRNAs. <i>Radiation Research</i> , 2021, 195, 324-333.	0.7	10
17	Immune infiltrate diversity confers a good prognosis in follicular lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3573-3585.	2.0	8
18	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. <i>British Journal of Cancer</i> , 2021, 125, 85-93.	2.9	6

#	ARTICLE	IF	CITATIONS
19	An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 158, 112-117.	0.3	15
20	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021, 148, 260-276.	1.3	21
21	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.3	11
22	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. <i>BMC Urology</i> , 2021, 21, 96.	0.6	5
23	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.4	33
24	A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy. <i>Computers in Biology and Medicine</i> , 2021, 135, 104624.	3.9	3
25	Impact of hypoxia on cervical cancer outcomes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1459-1470.	1.2	17
26	The effect of hypoxia on PD-L1 expression in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 1271.	1.1	14
27	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 179-190.	3.0	71
28	Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 539-544.	2.9	35
29	Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue. <i>Scientific Reports</i> , 2020, 10, 17258.	1.6	10
30	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	1.3	15
31	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16
32	Independence of HIF1a and androgen signaling pathways in prostate cancer. <i>BMC Cancer</i> , 2020, 20, 469.	1.1	25
33	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. <i>British Journal of Radiology</i> , 2020, 93, 20190250.	1.0	2
34	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	1.3	1
35	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	1.3	10
36	Tumour Hypoxia. <i>Clinical Oncology</i> , 2019, 31, 595-599.	0.6	15

#	ARTICLE	IF	CITATIONS
37	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.4	69
38	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
39	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.4	23
40	Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 1-8.	0.9	14
41	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5315-5328.	3.2	81
42	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.3	53
43	Radiogenomics in the Era of Advanced Radiotherapy. <i>Clinical Oncology</i> , 2019, 31, 319-325.	0.6	20
44	Guidelines for using sigQC for systematic evaluation of gene signatures. <i>Nature Protocols</i> , 2019, 14, 1377-1400.	5.5	23
45	Dynamics of circulating vascular endothelial growth factor predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1781-1789.	1.1	3
46	Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring. <i>Radiotherapy and Oncology</i> , 2019, 130, 56-61.	0.3	15
47	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	1.1	21
48	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. <i>Clinical Oncology</i> , 2019, 31, 9-16.	0.6	30
49	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 957-963.	0.4	5
50	The hypoxia marker CAIX is prognostic in the UK phase III Vortex-Biobank cohort: an important resource for translational research in soft tissue sarcoma. <i>British Journal of Cancer</i> , 2018, 118, 698-704.	2.9	20
51	A new approach for modeling patient overall radiosensitivity and predicting multiple toxicity endpoints for breast cancer patients. <i>Acta Oncologica</i> , 2018, 57, 604-612.	0.8	4
52	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	2.7	132
53	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 274-284.	0.4	50
54	Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2018, 110, 14-30.	3.0	177

#	ARTICLE	IF	CITATIONS
55	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 389-401.	1.2	5
56	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. <i>Oncotarget</i> , 2018, 9, 3946-3955.	0.8	35
57	Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. <i>Scientific Reports</i> , 2018, 8, 16804.	1.6	37
58	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	5.8	43
59	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. <i>PLoS ONE</i> , 2018, 13, e0194841.	1.1	7
60	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
61	Radiation biology and oncology in the genomic era. <i>British Journal of Radiology</i> , 2018, 91, 20170949.	1.0	25
62	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88
63	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. <i>International Journal of Particle Therapy</i> , 2018, 5, 103-113.	0.9	6
64	Ionizing radiation biomarkers in epidemiological studies – An update. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 771, 59-84.	2.4	118
65	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>British Journal of Cancer</i> , 2017, 116, 649-657.	2.9	9
66	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4761-4768.	3.2	107
67	The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K _{trans} in cervical cancer is explained by plasma flow rather than vessel permeability. <i>British Journal of Cancer</i> , 2017, 116, 1436-1443.	2.9	25
68	Radiogenomics and radiotherapy response modeling. <i>Physics in Medicine and Biology</i> , 2017, 62, R179-R206.	1.6	43
69	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. <i>Frontiers in Oncology</i> , 2017, 7, 83.	1.3	36
70	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. <i>Oncotarget</i> , 2017, 8, 14416-14427.	0.8	70
71	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. <i>Radiotherapy and Oncology</i> , 2016, 121, 440-446.	0.3	15
72	Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. <i>Cancer Letters</i> , 2016, 382, 95-109.	3.2	68

#	ARTICLE	IF	CITATIONS
73	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. <i>British Journal of Cancer</i> , 2016, 114, 1165-1174.	2.9	17
74	Pitfalls in Prediction Modeling for Normal Tissue Toxicity in Radiation Therapy: An Illustration With the Individual Radiation Sensitivity and Mammary Carcinoma Risk Factor Investigation Cohorts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1466-1476.	0.4	13
75	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. <i>EBioMedicine</i> , 2016, 10, 150-163.	2.7	69
76	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. <i>Cancer Research</i> , 2016, 76, 6598-6606.	0.4	128
77	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 431-439.	0.3	98
78	Improved accuracy and precision of tracer kinetic parameters by joint fitting to variable flip angle and dynamic contrast enhanced MRI data. <i>Magnetic Resonance in Medicine</i> , 2016, 76, 1270-1281.	1.9	12
79	Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity. <i>Clinical Cancer Research</i> , 2016, 22, 1413-1420.	3.2	16
80	Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas. <i>Oncotarget</i> , 2016, 7, 63106-63123.	0.8	12
81	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2015, 136, 709-720.	2.3	24
82	FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. <i>BMC Research Notes</i> , 2015, 8, 676.	0.6	10
83	Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1515-1524.	5.1	90
84	Imaging tumour hypoxia with positron emission tomography. <i>British Journal of Cancer</i> , 2015, 112, 238-250.	2.9	272
85	Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma. <i>Laryngoscope</i> , 2015, 125, E8-15.	1.1	22
86	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. <i>Clinical Oncology</i> , 2015, 27, 579-587.	0.6	37
87	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2015, 51, 508-513.	0.8	20
88	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1084-1092.	0.4	64
89	Biomarkers and Imaging for Precision Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 545-546.	0.6	4
90	Radiogenomics: the search for genetic predictors of radiotherapy response. <i>Future Oncology</i> , 2014, 10, 2391-2406.	1.1	63

#	ARTICLE	IF	CITATIONS
91	Expression of hypoxia-inducible factor-1 α predicts benefit from hypoxia modification in invasive bladder cancer. <i>British Journal of Cancer</i> , 2014, 111, 437-443.	2.9	38
92	Investigation of the epithelial to mesenchymal transition markers S100A4, vimentin and Snail1 in gastroesophageal junction tumors. <i>Ecological Management and Restoration</i> , 2014, 27, 485-492.	0.2	6
93	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. <i>Translational Oncology</i> , 2014, 7, 55-64.	1.7	16
94	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 145-156.	1.4	51
95	STROGAR â€“ STrengthening the Reporting Of Genetic Association studies in Radiogenomics. <i>Radiotherapy and Oncology</i> , 2014, 110, 182-188.	0.3	59
96	The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. <i>Clinical Oncology</i> , 2014, 26, 739-742.	0.6	73
97	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. <i>Nature Genetics</i> , 2014, 46, 891-894.	9.4	114
98	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 709-713.	0.4	99
99	Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: Potential to guide treatment? A systematic review. <i>Oral Oncology</i> , 2014, 50, 963-970.	0.8	74
100	NIMRAD â€“ A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer. <i>Clinical Oncology</i> , 2014, 26, 344-347.	0.6	70
101	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2014, 111, 178-185.	0.3	128
102	Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines. <i>PLoS ONE</i> , 2014, 9, e86329.	1.1	43
103	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.. <i>Journal of Clinical Oncology</i> , 2014, 32, 276-276.	0.8	0
104	Molecular and cellular processes underlying the hallmarks of head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 2585-2593.	0.8	33
105	The Prognostic Significance of the Biomarker p16 in Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Oncology</i> , 2013, 25, 630-638.	0.6	53
106	RAPPER: The Radiogenomics of Radiation Toxicity. <i>Clinical Oncology</i> , 2013, 25, 431-434.	0.6	28
107	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4879-4888.	3.2	214
108	FTIR microspectroscopy of selected rare diverse subâ€“variants of carcinoma of the urinary bladder. <i>Journal of Biophotonics</i> , 2013, 6, 73-87.	1.1	38

#	ARTICLE	IF	CITATIONS
109	An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. <i>European Journal of Cancer</i> , 2013, 49, 1741-1751.	1.3	15
110	Poor Prognosis Associated With Human Papillomavirus 16 Genotypes in Cervical Carcinoma Cannot Be Explained by Intrinsic Radiosensitivity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e223-e229.	0.4	9
111	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 40-47.	0.3	54
112	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 156-165.	1.3	36
113	Lack of Prognostic Effect of Carbonic Anhydrase-9, Hypoxia Inducible Factor-1 and Bcl-2 in 286 Patients with Early Squamous Cell Carcinoma of the Glottic Larynx Treated with Radiotherapy. <i>Clinical Oncology</i> , 2013, 25, 59-65.	0.6	20
114	Susuk charms? A case report. <i>British Dental Journal</i> , 2013, 215, 13-15.	0.3	6
115	A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-7.	0.7	5
116	The Case for Including Bowel Urgency in Toxicity Reporting After Pelvic Cancer Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 827-833.	2.3	3
117	Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population. <i>British Journal of Cancer</i> , 2012, 107, 1125-1130.	2.9	14
118	The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2012, 107, 1766-1775.	2.9	34
119	Will SNPs be useful predictors of normal tissue radiosensitivity in the future?. <i>Radiotherapy and Oncology</i> , 2012, 105, 283-288.	0.3	20
120	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. <i>Lancet Oncology</i> , The, 2012, 13, 65-77.	5.1	202
121	Standardized Total Average Toxicity Score: A Scale- and Grade-Independent Measure of Late Radiotherapy Toxicity to Facilitate Pooling of Data From Different Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1065-1074.	0.4	63
122	Osteoradionecrosis in Head-and-Neck Cancer Has a Distinct Genotype-Dependent Cause. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1479-1484.	0.4	24
123	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2012, 105, 289-295.	0.3	65
124	Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. <i>British Journal of Cancer</i> , 2012, 107, 684-694.	2.9	116
125	A replicated association between polymorphisms near TNF and risk for adverse reactions to radiotherapy. <i>British Journal of Cancer</i> , 2012, 107, 748-753.	2.9	66
126	Lysyl Oxidase: From Basic Science to Future Cancer Treatment. <i>Cell Structure and Function</i> , 2012, 37, 75-80.	0.5	89

#	ARTICLE	IF	CITATIONS
127	Statistical Considerations of Optimal Study Design for Human Plasma Proteomics and Biomarker Discovery. <i>Journal of Proteome Research</i> , 2012, 11, 2103-2113.	1.8	53
128	Genome-Wide Association Studies and Prediction of Normal Tissue Toxicity. <i>Seminars in Radiation Oncology</i> , 2012, 22, 91-99.	1.0	23
129	Genetics and genomics of radiotherapy toxicity: towards prediction. <i>Genome Medicine</i> , 2011, 3, 52.	3.6	144
130	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: A cohort study based on 994 patients. <i>Radiotherapy and Oncology</i> , 2011, 100, 108-115.	0.3	62
131	Perfusion Estimated With Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely With Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1176-1183.	0.4	63
132	Head and neck cancer—Part 1: Epidemiology, presentation, and preservation. <i>Clinical Otolaryngology</i> , 2011, 36, 65-68.	0.6	56
133	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. <i>British Journal of Cancer</i> , 2011, 104, 1168-1177.	2.9	244
134	Exon-array profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffin-embedded tumour samples. <i>British Journal of Cancer</i> , 2011, 104, 971-981.	2.9	29
135	Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility. <i>British Journal of Cancer</i> , 2011, 104, 1319-1324.	2.9	26
136	hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. <i>Cancer</i> , 2010, 116, 2148-2158.	2.0	215
137	A comparison of tracer kinetic models for T_1 -weighted dynamic contrast-enhanced MRI: Application in carcinoma of the cervix. <i>Magnetic Resonance in Medicine</i> , 2010, 63, 691-700.	1.9	92
138	Establishment of a Radiogenomics Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1295-1296.	0.4	118
139	Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. <i>Histopathology</i> , 2010, 56, 893-899.	1.6	68
140	Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. <i>British Journal of Cancer</i> , 2010, 102, 23-26.	2.9	52
141	Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. <i>British Journal of Cancer</i> , 2010, 102, 428-435.	2.9	440
142	Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2881-2888.	0.8	72
143	Use of multiple biological markers in radiotherapy-treated head and neck cancer. <i>Journal of Laryngology and Otology</i> , 2010, 124, 650-658.	0.4	8
144	Epigenetic downregulation of human disabled homolog 2 switches TGF- β 2 from a tumor suppressor to a tumor promoter. <i>Journal of Clinical Investigation</i> , 2010, 120, 2842-2857.	3.9	87

#	ARTICLE	IF	CITATIONS
145	Head and neck cancer--Part 1: Epidemiology, presentation, and prevention. <i>BMJ: British Medical Journal</i> , 2010, 341, c4684-c4684.	2.4	216
146	Head and neck cancer--Part 2: Treatment and prognostic factors. <i>BMJ: British Medical Journal</i> , 2010, 341, c4690-c4690.	2.4	72
147	Expression of hypoxia-inducible factor 1 α in thyroid carcinomas. <i>Endocrine-Related Cancer</i> , 2010, 17, 61-72.	1.6	84
148	No association between SNPs regulating TGF- β 1 secretion and late radiotherapy toxicity to the breast: Results from the RAPPER study. <i>Radiotherapy and Oncology</i> , 2010, 97, 9-14.	0.3	54
149	Establishment of a radiogenomics consortium. <i>Radiotherapy and Oncology</i> , 2010, 94, 117-118.	0.3	56
150	Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2010, 97, 136-142.	0.3	26
151	Genetic Predictors of Normal Tissue Response to Radiotherapy. , 2010, , 127-135.		1
152	Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 197.	0.8	20
153	Clinical Impact of Tumour Involvement of the Anastomotic Doughnut in Oesophagogastric Cancer Surgery. <i>Annals of the Royal College of Surgeons of England</i> , 2009, 91, 195-200.	0.3	3
154	Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 303-309.	1.9	22
155	The radiobiology/radiation protection interface in healthcare. <i>Journal of Radiological Protection</i> , 2009, 29, A1-A20.	0.6	12
156	The degree of circumferential tumour involvement as a prognostic factor in oesophageal cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 368-373.	0.6	17
157	Exon Array Analysis of Head and Neck Cancers Identifies a Hypoxia Related Splice Variant of LAMA3 Associated with a Poor Prognosis. <i>PLoS Computational Biology</i> , 2009, 5, e1000571.	1.5	37
158	Comparison of predicted and clinical response to radiotherapy: A radiobiology modelling study. <i>Acta Oncologica</i> , 2009, 48, 584-590.	0.8	10
159	Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. <i>Nature Reviews Cancer</i> , 2009, 9, 134-142.	12.8	593
160	Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in MRI: A Potential Novel Biomarker of Oxygenation Changes in Solid Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1209-1215.	0.4	107
161	Point: Why choose pulsed-dose-rate brachytherapy for treating gynecologic cancers?. <i>Brachytherapy</i> , 2009, 8, 269-272.	0.2	5
162	Measurement tools for gastrointestinal symptoms in radiation oncology. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 36-40.	0.5	23

#	ARTICLE	IF	CITATIONS
163	Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging. , 2009, , 295-313.		1
164	Prognostic Significance of Tumor Hypoxia Inducible Factor α 1 β Expression for Outcome After Radiotherapy in Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1551-1559.	0.4	49
165	Hypoxia-associated markers in gastric carcinogenesis and HIF-2 β in gastric and gastro-oesophageal cancer prognosis. British Journal of Cancer, 2008, 98, 965-973.	2.9	31
166	Epidermal growth factor receptor-targeted therapy. British Journal of Radiology, 2008, 81, S36-S44.	1.0	27
167	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.4	349
168	Exploiting sample variability to enhance multivariate analysis of microarray data. Bioinformatics, 2007, 23, 2733-2740.	1.8	4
169	The Genomics Revolution and Radiotherapy. Clinical Oncology, 2007, 19, 470-480.	0.6	54
170	Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. International Journal of Radiation Oncology Biology Physics, 2007, 67, 84-90.	0.4	77
171	Tumor Expression of Major Vault Protein is an Adverse Prognostic Factor for Radiotherapy Outcome in Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 133-140.	0.4	16
172	Hypoxia-inducible factor-1 β expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. British Journal of Cancer, 2007, 96, 95-103.	2.9	94
173	Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia \rightarrow dysplasia \rightarrow adenocarcinoma sequence. British Journal of Cancer, 2007, 96, 1377-1383.	2.9	46
174	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clinical Otolaryngology, 2007, 32, 337-345.	0.6	52
175	The prognostic value of pimonidazole and tumour pO ₂ in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 2006, 80, 123-131.	0.3	98
176	No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix. British Journal of Cancer, 2006, 94, 115-120.	2.9	8
177	Radiosensitivity, Radiogenomics and RAPPER. Clinical Oncology, 2006, 18, 525-528.	0.6	46
178	Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 331-338.	0.4	44
179	Imaging vascular physiology to monitor cancer treatment. Critical Reviews in Oncology/Hematology, 2006, 58, 95-113.	2.0	53
180	Translational research in radiotherapy trials. British Journal of Radiology, 2006, 79, 716-718.	1.0	2

#	ARTICLE	IF	CITATIONS
181	Hypoxia in head and neck cancer. <i>British Journal of Radiology</i> , 2006, 79, 791-798.	1.0	76
182	Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer: Controversies and Future developments. <i>Clinical Oncology</i> , 2005, 17, 591-598.	0.6	23
183	Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. <i>British Journal of Cancer</i> , 2005, 92, 449-458.	2.9	18
184	The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy. <i>British Journal of Radiology</i> , 2005, Supplement_28, 50-54.	1.0	5
185	Is the hypoxia-inducible factor pathway important in gastric cancer?. <i>European Journal of Cancer</i> , 2005, 41, 2792-2805.	1.3	71
186	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. <i>Clinical Lung Cancer</i> , 2005, 7, 23-29.	1.1	22
187	Hypoxia-Inducible Factor 1 α Expression as an Intrinsic Marker of Hypoxia. <i>Clinical Cancer Research</i> , 2004, 10, 8405-8412.	3.2	123
188	The potential of positron-emission tomography to study anticancer-drug resistance. <i>Nature Reviews Cancer</i> , 2004, 4, 457-469.	12.8	35
189	Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[11C]-thymidine. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2004, 1705, 91-102.	3.3	10
190	Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation. <i>Radiotherapy and Oncology</i> , 2004, 70, 311-317.	0.3	6
191	Combretastatin A4 phosphate. <i>Anti-Cancer Drugs</i> , 2004, 15, 179-187.	0.7	115
192	Positron emission tomography (PET) and anticancer drug development. <i>Discovery Medicine</i> , 2004, 4, 303-6.	0.5	0
193	GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. <i>International Journal of Cancer</i> , 2003, 104, 85-91.	2.3	205
194	Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 502-510.	0.4	56
195	Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. <i>British Journal of Cancer</i> , 2003, 89, 870-876.	2.9	100
196	Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. <i>Radiotherapy and Oncology</i> , 2003, 67, 35-44.	0.3	140
197	Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. <i>Radiotherapy and Oncology</i> , 2003, 69, 195-200.	0.3	35
198	Differential Expression of Cytokine Genes in Fibroblasts Derived from Skin Biopsies of Patients who Developed Minimal or Severe Normal Tissue Damage after Radiotherapy. <i>Radiation Research</i> , 2002, 157, 243-248.	0.7	34

#	ARTICLE	IF	CITATIONS
199	Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. <i>Radiotherapy and Oncology</i> , 2002, 62, 321-326.	0.3	22
200	Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. <i>International Journal of Radiation Biology</i> , 2002, 78, 341-346.	1.0	46
201	Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 759-767.	0.4	165
202	Short Report: A Morbidity Scoring System for Clinical Oncology Practice: Questionnaires produced from the LENT SOMA scoring system. <i>Clinical Oncology</i> , 2002, 14, 68-69.	0.6	23
203	Late Radiation Morbidity in a Patient with Carcinoma of the Cervix. <i>Clinical Oncology</i> , 2002, 14, 437-441.	0.6	0
204	Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines. <i>International Journal of Radiation Biology</i> , 2001, 77, 295-302.	1.0	25
205	Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 581-586.	0.4	79
206	Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: the significance of hypoxia on tumor control modelling. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 1109-1118.	0.4	37
207	Ability to undergo apoptosis does not correlate with the intrinsic radiosensitivity (SF2) of human cervix tumor cell lines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 503-509.	0.4	19
208	Incorporating biologic measurements (SF2, CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1113-1122.	0.4	54
209	Chromosomal radiosensitivity as a marker of predisposition to common cancers?. <i>British Journal of Cancer</i> , 2001, 84, 892-896.	2.9	99
210	Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 10-15.	0.4	72
211	Pretreatment plasma TGF β 21 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 991-995.	0.4	26
212	Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 13-19.	0.4	113
213	Expression of Ku70 correlates with survival in carcinoma of the cervix. <i>British Journal of Cancer</i> , 2000, 83, 1702-1706.	2.9	92
214	Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. <i>Radiotherapy and Oncology</i> , 2000, 57, 53-59.	0.3	197
215	Lack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 481-487.	0.4	16
216	A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 507-512.	0.4	30

#	ARTICLE	IF	CITATIONS
217	Changes in oxygenation during radiotherapy in carcinoma of the cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 119-126.	0.4	51
218	The immunohistochemical expression of DNA-PKcs and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 1005-1010.	0.4	37
219	The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. <i>British Journal of Cancer</i> , 1999, 80, 1400-1404.	2.9	22
220	Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: Independence from tumour radiosensitivity. <i>British Journal of Cancer</i> , 1999, 81, 354-358.	2.9	42
221	Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 96-100.	1.2	22
222	A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. <i>Radiotherapy and Oncology</i> , 1999, 51, 55-65.	0.3	55
223	Discussion. <i>Radiotherapy and Oncology</i> , 1999, 51, 109-111.	0.3	12
224	Discrimination of human tumor radioresponsiveness using low-dose rate irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 42, 1147-1153.	0.4	4
225	The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks. <i>Radiotherapy and Oncology</i> , 1998, 47, 271-276.	0.3	39
226	The intrinsic radiosensitivity of normal and tumour cells. <i>International Journal of Radiation Biology</i> , 1998, 73, 409-413.	1.0	49
227	The biology of photodynamic therapy. <i>Physics in Medicine and Biology</i> , 1997, 42, 913-935.	1.6	98
228	Cellular radiosensitivity in human severe-combined-immunodeficiency (SCID) syndromes. <i>Radiotherapy and Oncology</i> , 1997, 42, 53-57.	0.3	8
229	A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 1137-1144.	0.4	36
230	The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 841-846.	0.4	57
231	A Comparison of the Radiosensitivity of Lymphocytes from Normal Donors, Cancer Patients, Individuals with Ataxia-telangiectasia (A-T) and A-T Heterozygotes. <i>International Journal of Radiation Biology</i> , 1995, 68, 197-203.	1.0	96
232	Implications of Delayed Reproductive Cell Death (Lethal Mutations/Genomic Instability) for the Interpretation of Tissue Responses. <i>International Journal of Radiation Biology</i> , 1995, 68, 363-367.	1.0	11
233	Relationships between the Cytotoxic Effects of Restriction Endonucleases and Radiation on Mammalian Cells. <i>International Journal of Radiation Biology</i> , 1995, 67, 327-334.	1.0	3
234	Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. <i>Radiotherapy and Oncology</i> , 1995, 37, 1-9.	0.3	143

#	ARTICLE	IF	CITATIONS
235	Apoptosis as predictor of response to radiotherapy in cervical carcinoma. <i>Lancet, The</i> , 1994, 344, 472.	6.3	47
236	Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. <i>Radiotherapy and Oncology</i> , 1994, 30, 11-16.	0.3	27
237	Prediction of radiotherapy response using SF2: Is it methodology or mythology?. <i>Radiotherapy and Oncology</i> , 1994, 31, 86-88.	0.3	6
238	Use of Low-dose Rate Irradiation to Measure the Intrinsic Radiosensitivity of Human T-lymphocytes. <i>International Journal of Radiation Biology</i> , 1993, 64, 375-383.	1.0	37
239	Use of an Internal Standard in Comparative Measurements of the Intrinsic Radiosensitivities of Human T-lymphocytes. <i>International Journal of Radiation Biology</i> , 1993, 64, 385-391.	1.0	27
240	A Potential Pitfall in the Use of Electroporation: Cellular Radiosensitization by Pulsed High-voltage Electric Fields. <i>International Journal of Radiation Biology</i> , 1992, 61, 329-334.	1.0	13
241	MECHANISMS BEHIND THE RESISTANCE OF SPHEROIDS TO PHOTODYNAMIC TREATMENT: A FLOW CYTOMETRY STUDY. <i>Photochemistry and Photobiology</i> , 1992, 55, 425-430.	1.3	20
242	Prediction of cervical carcinoma response to radiotherapy. <i>Lancet, The</i> , 1991, 338, 818.	6.3	54
243	Low-density Lipoprotein Uptake and the Sensitivity to Photodynamic Treatment of Cultured Endothelial Cells. <i>International Journal of Radiation Biology</i> , 1991, 60, 25-28.	1.0	5
244	Comparison of Two Methods to Assess Tumour Vasculature in Human Cervical Carcinoma. <i>International Journal of Radiation Biology</i> , 1991, 60, 169-173.	1.0	4
245	The lower radiosensitivity of mouse kidney cells irradiated in vivo than in vitro: A cell contact effect phenomenon. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 20, 1243-1248.	0.4	16
246	A Comparison of the Sensitivity to Photodynamic Treatment of Endothelial and Tumour Cells in Different Proliferative States. <i>International Journal of Radiation Biology</i> , 1990, 58, 145-156.	1.0	53
247	Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. <i>Cancer Letters</i> , 1990, 55, 159-163.	3.2	9
248	Radiosensitivity testing of primary cervical carcinoma: evaluation of intra- and inter-tumour heterogeneity. <i>Radiotherapy and Oncology</i> , 1990, 18, 349-356.	0.3	71
249	Evaluation of Surviving Fraction at 2 Gy as a Potential Prognostic Factor for the Radiotherapy of Carcinoma of the Cervix. <i>International Journal of Radiation Biology</i> , 1989, 56, 761-765.	1.0	70
250	THE PHOTODYNAMIC EFFECTS OF PHOTOFRIN II, HEMATOPORPHYRIN DERIVATIVE, HEMATOPORPHYRIN, AND TETRASODIUM-MESO-TETRA(4-SULFONATOPHENYL)PORPHINE in vitro... <i>Photochemistry and Photobiology</i> , 1989, 49, 169-174.	1.3	21
251	FLOW CYTOMETRIC ANALYSIS OF INTRACELLULAR HEMATOPORPHYRIN DERIVATIVE IN HUMAN TUMOR CELLS AND MULTICELLULAR SPHEROIDS. <i>Photochemistry and Photobiology</i> , 1989, 50, 665-669.	1.3	15
252	Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 14, 1213-1219.	0.4	16

#	ARTICLE	IF	CITATIONS
253	Cell Survival Characteristics of a Human Colon Adenocarcinoma Cell Line after Photodynamic Treatment: A Comparison of Photofrin II and TPPS. <i>International Journal of Radiation Biology</i> , 1988, 54, 621-634.	1.0	29
254	A Human Colon Adenocarcinoma Xenograft's Radiation Response, Cellular Composition, and Tumor Disaggregation. <i>Journal of the National Cancer Institute</i> , 1987, . .	3.0	5
255	The Radiation Response of a Human Colon Adenocarcinoma Grown in Monolayer, as Spheroids, and in Nude Mice. <i>Radiation Research</i> , 1987, 112, 105.	0.7	35
256	A comparison of adriamycin and mAMSA. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 20, 109-14.	1.1	6
257	A radiobiological comparison of human tumor soft-agar clonogenic assays. <i>International Journal of Cancer</i> , 1986, 37, 897-903.	2.3	28